BioSpace News Archive

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced the signing of a license agreement granting Cumulus Oncology exclusive worldwide rights to develop and commercialize VER250840, a novel, oral, selective, preclinical Chk1 Kinase Inhibitor discovered using Ligand’s Vernalis Design Platform (VDP)

Orexo AB (publ.), the fully integrated specialty pharmaceutical company addressing opioid addiction and pain, today announces that the company will be presenting at the following events taking place in May and June.

The National Association of Specialty Pharmacy (NASP) is extremely disappointed the administration did not initiate much needed reforms to ensure Medicare beneficiaries begin paying less at the pharmacy counter in 2020

Table Mountain Casino, located in Central California, recently presented the nationally ranked children’s healthcare network, Valley Children’s Healthcare, with a donation for $10,000.

The Epilepsy Foundation is hosting its 13th Annual Care & Cure Benefit on May 30, 2019, at 6 p.m. at the Beverly Wilshire Hotel in Beverly Hills.

Franek Technologies has configured an uninterruptible power supply unit to support the Applied Biosystems 3500XL Genetic Analyzer and Controller

Impel NeuroPharma, a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies that unlock the full potential of proven medicines for patients living with central nervous system (CNS) disorders with high unmet medical needs, today announced a poster presentation at the upcoming American Psychiatric Association (APA) Annual Meeting,

There are more than 15 million cancer survivors in the world today, each living with the systemic impacts of their cancer treatments

The Medicrea Group, pioneering the transformation of spinal surgery through artificial Intelligence, predictive modeling and patient specific implants with its UNiD™ ASI proprietary software platform, services and technologies, reports its unaudited results for the first quarter of 2019.

Aurinia Pharmaceuticals Inc. announced that Mr. Peter Greenleaf, Chief Executive Officer, will present a corporate overview at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019 at 6:30am PT (9:30am ET) in New York, NY.